Pharmacydude over on ST has a post commenting on tomorrow's conference. He is suggesting that it will be basically a dog and pony show to try to firm up the stock price but if there is nothing of substance to the conference it may have the reverse effect showing desperation. He makes a good point about management not proceeding with buying shares but urging us to do so.

Nice.  I was once asked for my preference between France and Italy, and although I personally would not mind either I feel a bit more comfortable in France, only because I speak the language.  Crazy since my Mom was Italian. 

Yep, when I see those damn commercials, they always remind me that I screwed up when I didn't move to France upon retirement. 

That's fine but Amarin is going to have to be much more attractive to garner any interest. It is too soon, as we need to get a number of things in order. More reimbursement decisions in ROW (positive ones) and more of an idea of what is happening with the U.S. market, and any new possible formulations to bring to market.

Don't know if there is another bill that has any many signers/co-sponsors/whatever they call it, so hopefully it happens.  

SD, good question. No question that I am somewhat unhappy/frustrated about PFE's price movement.

First let me say that I don't know what is really going on behind the scenes with Starboard, Bourla, and others in the boardroom, so I will confine my thoughts to other things. I will give an example at the end of this but no question PFE is out of favor with investors and that is also partly because many are chasing momentum stocks. Like you say, they had great earnings this past qtr and the next qtr will be great in comparison to the same qtr last year. They have been cutting expenses, which is good and have almost 60 drugs in either phase II or phase III trials. No question I should have taken some or all off the table when they hit $60 almost exactly 3 years ago, but dumb me.

In Feb, Mar, April of this year I bought BMY in the high 40's and low 50's. It proceeded to go down (looking like another PFE) and in July I bought more at $40. Well, BMY has turned it around in the last month and today, after ABBV announced that their schizo drug missed targets, the stock jumped to $60. For quite a while things looked just as dire for BMY. I guess my experience with BMY this year has not only given me hope for the future of PFE but kept me calm while watching it go down. So, right now, I am sticking with PFE (and sucking up the divvy in the meantime) assuming and thinking that its time will come. With all those drugs in trials some have to hit just as some will fail.

When I look at my Fidelity site and the research section on PFE I see most if not all analysts rating it highly (that does scare me a tiny bit) and they have a thing called Trefis Valuation Estimate (have no idea what that is) and it pegs fair value at this very instant at $36.22. That is about $10 higher than the stock closed today. I don't presume to know how to unlock the value there, but I definitely think there is more value in the company than $26 a share. Plus if we expect interest rates to continue to come down the 6%+ div should ultimately drive investors looking for yield into the stock. Hope this didn't sound to rosy. I guess you didn't catch me on a bad day. Are your thoughts on PFE much different?

Not that I'm aware. Do know we have ability in ghat regard since we have huge margins.  Maybe the focus is so much on selling the company that they don't want to fiddle with that. 

Yes it has looked like Powell is developing a spine (although he did cave during Trump's first term and may yet again) but saw story this morning Musk and others pushing to have Fed under control of Pres:

https://nypost.com/2024/11/11/business/elon-musk-backs-call-to-place-fed-under-trumps-control/


Hopefully with workforce reduction and Tang onboard we can get Auphie moving and sold before Vera enters the scene. 

I guess those betting on acceptance had all piled in before today, so no more buying pressure. Have to see how the next few days shake out.  

Curious to hear what they have to say at the Investors' Conference.  Better hear something new.  

Other than passage of the Kidney Act I should say. 

I guess this acceptance was built-in by the rise from 25 cents to 60 cents.  Not sure what other catalyst can get us to a buck?

Well put

Tanking again this morning possibly because UNCY's drug got accepted for review by FDA

Thanks for posting.  Saw that a few min ago.  However it doesn't yet seem to be moving the stock in pm yet.  News not reached enough people?   

Thanks Kiwi. Guess I was theown off by the term "small" rather than the usual %.  Made me think it was in a spot that was too narrow or small for a stent, but you cleared that up.  

Of course here in the US a decision on CAGB  is many times determined by gge type of insurance, or absence of it, the patient has.  

Thanks for posting this from Australia. One thing caught my eye and that was the comment that the blockage was too small for stents and only option was conservative management. I wonder why CAGB was not an option, not that I would want that but just wondering why that was not an option.

Yep, best healthcare that lobbyists' money can buy. 

Stocktwits is a fire over this post:

https://x.com/tonkhalife/status/1855663911237747004?s=46&t=VJb6Ff31iAXg1p7xDcqPUQ

Thanks for posting.  The more pressure put on Congress the better chance (never great) that the Kidney Act gets passed.  All it takes though is someone with a wild hair up their arse to block the thing. 

Happened to me this past week.  The House was set to vote on eliminating WEP for SS, and 2 from the Freedom Caucus put a block.  Last I heard, upset so many that Johnson promises to bring it to a vote this week. Shall see. 

Sleven, sure. Of course companies and people have ways to get around problems like that. If not, your supposition is correct that the cost may increase.

Sure seems like a bunch of late. Hard to imagine the Generics claiming they are locked out of supply, because I doubt Amarin is using all of this.

Thanks a bunch for that information.  It brings up two questions:

First, has anyone heard whether Hikma has requested a stay?

Secondly, if not, has the court set dates for discovery or other motions restarting the case?

Thanks. That is what I thought, sometime in January.  So I am not sure what North is referring to with his Nov 2024 date.  

North I am a little confused about this.  Is that the date the 90 window for Hikma to request a Supreme Court appeal hearing ends?  

I guess we are good.  But never sure in this bizarro world.  

It is hard imagine much interest in acquiring Amarin at this juncture, before Amarin makes some strides in ROW (or something on the legal front in the U.S.), unless Denner orchestrates a giveaway.

Hopefully, there are some positive developments divulged in this coming Investors' Conference. Will be listening intently.

Good luck to us all.  I have plenty right now.  

Great work Kiwi.  Sort of jives with the Nov 14 or 16 date.  Now we just have to hope for radio silence from UNCY this weekend. Tape their mouths shut.  

Why do you think the bad news for ARDX is not spilling over to UNCY?

Kiwi, you are giving us a glimmer of hope if there is a possibility of a longer time frame for notice if approved.  Maybe that is why the stock has firmed up more this week with the realization that there won't be a denial.  Let us know if you find approval yields a longer time frame.  Not sure what a poster I read on yahoo was referring to but their contention that Nov 16 could be the expected date, so not sure if that has any merit.  

Almost 5 million shares traded in first half hour.  

Still no news. So either someone has the dates wrong or they are waiting for the close to release bad news on a Friday afternoon into the weekend like all other companies with bad news

Bug drop and seeing posters elsewhere saying court case has been dismissed. Only hope now is Kidney Act.  Disaster du Jour. 

A Fierce Pharma article dated today about the restructuring, (As a side note, I didn't know that sales were flat from 2Q to 3Q so I will have to go back and look at that again):

https://www.amazon.com/YOGINGO-Pack-Christmas-Stockings-Personalized/dp/B0D86JV9ZQ/ref=sr_1_41?crid=1M8FRWGP1DKNR&dib=eyJ2IjoiMSJ9.P8XAFzm46Eai6mU0rxi3J657M6xzme7YFrtWeGO8Ahf5iEyxaa59x5UEfo2Pv8ou-RabXdTMjVcejZZbdETKHNdygdyXHKxl3FfdVnbe37_D9DIhEzbXxH_Y_3X2D3yhJ8hB3G35XqSNC8s-KwqGY0-YtcJAX61IcWZ3f5CCGjV6NMH9Q2hRVb2_YkHUwdBtFjDswLBWzLX37K9qkZGoRXr1XFshtSY2Jebev6a2fHYA77wocgoYlpiDeLzCMls71OzOwlD96yOHCo95Z26K0puFLkBiC_h6ptHEKLvSwUQ.AF18_HCbKa0FQd125MB3rir03ZFnegC_Hx0_-2CkKvI&dib_tag=se&keywords=christmas%2Bstockings&qid=1731015416&sprefix=christmas%2Bstocking%2Caps%2C191&sr=8-41&th=1

"After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring.

Aurinia on Thursday unveiled a strategic overhaul that will slash 45% of the Canadian biotech’s entire workforce.

Aurinia expects the trimming will save it more than $40 million in annual operating expenses. The move will allow the company to focus on the commercialization of its lupus nephritis drug Lupkynis and the development of AUR200, an autoimmune disease candidate that Aurinia recently salvaged from its garbage can.

The cost savings will strengthen Aurinia’s financial position and “provide more flexibility to engage in future business building activities,” CEO Peter Greenleaf said on an investor call Thursday.

This marks the second round of layoffs at Aurinia in less than a year. Back in February, following a fruitless search for a potential buyer, Aurinia decided to reduce its headcount by about 25%.

At that time, Aurinia had decided to discontinue AUR200 but later revived the APRIL/BAFF inhibitor. Now, CEO Greenleaf in a Thursday statement said the organizational overhaul will help Aurinia accelerate the development of AUR200, an “important pipeline product.”

Greenleaf’s leadership at Aurinia was put into serious question when he and three other Aurinia board directors lost majority stockholder support during the company’s annual meeting. The company’s proposed executive pay packages also failed to garner majority investor backing.

As required by Aurinia’s company policy, the four directors submitted their resignations. But the board, while accepting the resignations of the other three members, argued that “there are exceptional circumstances that warrant the rejection of Mr. Greenleaf’s conditional resignation,” it said in a September securities filing. As a result, Greenleaf stayed on.

RELATED

Investor activism resurfaces at Aurinia after CEO’s board role, exec pay lost majority support
Amid broader investor disapproval of Aurinia’s leadership team, an activist shareholder who owned 2.2% of the company’s stock in August called for board and management changes, blasting them for “unchecked spending, ineffective leadership, and a clear lack of strategic direction.”

Lupkynis is currently Aurinia’s single commercial product, with third-quarter sales of $55.5 million. The number represents 36% year-over-year growth but is flat compared with $55 million in the second quarter. The number of patients on the therapy has grown about 25% to 2,422 as of the end of September, Greenleaf told investors on a call Thursday.

“This significant year-over-year growth was driven by patients restarting Lupkynis after being off therapy for an extended period of time, as well as hospital fills and maintaining high persistency rates year over year,” he said.

With total product revenue of $158.6 million in the first nine months of this year, Aurinia has kept its full-year guidance range of $210 million to $220 million.

As to AUR200, the company in September dosed the first participant in a phase 1 single-ascending dose study, with data expected in the first half of 2025. Aurinia has not disclosed the indications that it plans to develop AUR200 in. "

JRoon, don't presume to know what Always is referring to, but my guess would be the discussion and exwannabe's latest post highlighting how the system (script writing, insurance, pharmacies) is conspiring or at least enabled to be gamed to screw Vascepa with brand scripts getting substituted by generics in clear violation of patents but with nothing seemingly being able to be done. A runaway train.

Some similarities and some not when comparison to LaJolla.  One thing that is similar is they had a drug that in no way met sales expectations as is the case here.  But I assume that you don't mean that being "Tang'd" is necessarily bad unless someone has a high cost basis here.  

Not sure if you saw today that Powell of the Fed Reserve developed a backbone and is saying he won't step down if asked. 

Well for one they just reported earnings and not only have they gotten into the black, but revenues are increasing, unlike Amarin.  Secondly, their approved drug has no generic competition, again, unlike Amarin.  

Yes, hope it is not a misread or BS leak of FDA news and this craters after rejection.  Will hope for good news but always bracing for bad.  

So crazy.  How can a stock be up over 13% one day and down 5% in premarket the next on no news!

Announced a strategic restructuring to "focus on Lupkynis and AUR200".  What the hell were they focusing on before?

To me it sounds like they are clearing the decks to be acquired.